Copyright
©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Sep 5, 2025; 16(3): 107167
Published online Sep 5, 2025. doi: 10.4292/wjgpt.v16.i3.107167
Published online Sep 5, 2025. doi: 10.4292/wjgpt.v16.i3.107167
Table 1 Comparative analysis of baseline features
Characteristic | ERCP (n = 12) | PTBD (n = 21) | P value |
Severe cholangitis (n = 33) | 12 (36.4) | 21 (63.6) | |
Mean age (years) | 60.4 | 62.7 | 0.63 |
Female | 4 (33.3) | 8 (38.1) | 0.78 |
Male | 8 (66.7) | 13 (61.9) | |
Charlson Comorbidity Index score | 3.3 ± 2.4 | 5.0 ± 2.7 | 0.09 |
Comorbidities | |||
Hypertension | 7 (58.3) | 12 (57.1) | 0.94 |
Diabetes | 4 (33.3) | 8 (38.1) | 0.78 |
Ischemic heart disease | 1 (8.3) | 6 (28.6) | 0.17 |
Chronic kidney disease | 0 (0.0) | 2 (9.5) | 0.27 |
Chronic liver disease | 1 (8.3) | 1 (4.8) | 0.67 |
Nonalcoholic fatty liver disease | 1 (8.3) | 0 (0.0) | 0.17 |
Clinical features | |||
Abdominal pain | 8 (66.7) | 18 (85.7) | 0.19 |
Fever | 7 (58.3) | 13 (61.9) | 0.80 |
Jaundice | 5 (41.7) | 15 (71.4) | 0.09 |
Nausea and vomiting | 5 (41.7) | 5 (23.8) | 0.28 |
Weight loss | 1 (8.3) | 7 (33.3) | 0.10 |
Altered consciousness | 1 (8.3) | 5 (23.8) | 0.26 |
Lethargy | 0 (0.0) | 3 (14.3) | 0.17 |
Vitals | |||
Temperature | 37.0 ± 0.4 | 37.3 ± 0.4 | 0.11 |
Heart rate | 96.2 ± 14.8 | 102.3 ± 19.5 | 0.35 |
Mean arterial pressure | 64.9 ± 7.4 | 60.7 ± 4.6 | 0.05 |
Respiratory rate | 20.7 ± 6.1 | 20.6 ± 2.1 | 0.97 |
SpO2 | 95.1 ± 2.6 | 94.9 ± 1.3 | 0.79 |
Laboratory investigations | |||
Hemoglobin | 11.2 ± 2.8 | 10.3 ± 1.8 | 0.29 |
Total leukocyte count | 18.2 ± 7.8 | 18.2 ± 8.7 | 0.98 |
Platelets | 216.7 ± 126.3 | 223 ± 130.4 | 0.88 |
Prothrombin time | 15.6 ± 7.3 | 16.2 ± 8.4 | 0.83 |
Organ severity | |||
Cardiac dysfunction | 6 (50.0) | 17 (80.9) | 0.06 |
Hepatic dysfunction | 4 (33.3) | 10 (47.6) | 0.42 |
Renal dysfunction | 3 (25.0) | 8 (38.1) | 0.44 |
Hematological dysfunction | 3 (25.0) | 4 (19.1) | 0.68 |
Neurological dysfunction | 0 (0.0) | 3 (14.3) | 0.17 |
Pulmonary dysfunction | 0 (0.0) | 2 (9.6) | 0.27 |
Table 2 Technical success, complications and outcome of patients
Outcome | ERCP (n = 12) | PTBD (n = 21) | P value |
Technical success | 12 (100.0) | 21 (100.0) | |
Therapeutic success | 11 (91.7) | 12 (57.1) | 0.03 |
Complications | |||
Total complications | 2 (16.7) | 12 (57.1) | 0.02 |
Hospital acquired infections | 2 (16.7) | 11 (52.4) | 0.04 |
Pulmonary complications | 1 (8.3) | 6 (28.6) | 0.17 |
Dislodgement | 0 (0.0) | 3 (14.3) | 0.17 |
Arrhythmias | 0 (0.0) | 1 (4.7) | 0.44 |
Bleeding | 0 (0.0) | 2 (4.8) | 0.44 |
Mortality | 0 (0.0) | 5 (23.8) | 0.06 |
Readmission | 1 (8.3) | 4 (19.1) | 0.40 |
- Citation: Karim MM, Moatter S, Amin M, Parkash O. Comparison of endoscopic retrograde cholangiopancreatography drainage vs percutaneous transhepatic biliary drainage in severe cholangitis: A study from low-middle income country. World J Gastrointest Pharmacol Ther 2025; 16(3): 107167
- URL: https://www.wjgnet.com/2150-5349/full/v16/i3/107167.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i3.107167